Hyloris Pharmaceuticals (XBRU:HYL) Other Gross PPE : €2.15 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Other Gross PPE?

Hyloris Pharmaceuticals's Other Gross PPE for the quarter that ended in Dec. 2023 was €2.15 Mil.

Hyloris Pharmaceuticals's quarterly Other Gross PPE increased from Dec. 2022 (€0.18 Mil) to Jun. 2023 (€1.94 Mil) and increased from Jun. 2023 (€1.94 Mil) to Dec. 2023 (€2.15 Mil).

Hyloris Pharmaceuticals's annual Other Gross PPE increased from Dec. 2021 (€0.12 Mil) to Dec. 2022 (€0.18 Mil) and increased from Dec. 2022 (€0.18 Mil) to Dec. 2023 (€2.15 Mil).

Hyloris Pharmaceuticals Other Gross PPE Historical Data

The historical data trend for Hyloris Pharmaceuticals's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Other Gross PPE Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

0.03

0.02

0.12

0.18

2.15

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Gross PPE	Get a 7-Day Free Trial							0.12	0.20	0.18	1.94	2.15

Hyloris Pharmaceuticals Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Hyloris Pharmaceuticals (XBRU:HYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

52U:Germany

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.